414 related articles for article (PubMed ID: 23791641)
1. Amphotericin B-copper(II) complex as a potential agent with higher antifungal activity against Candida albicans.
Chudzik B; Tracz IB; Czernel G; Fiołka MJ; Borsuk G; Gagoś M
Eur J Pharm Sci; 2013 Aug; 49(5):850-7. PubMed ID: 23791641
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B-copper(II) complex shows improved therapeutic index in vitro.
Chudzik B; Czernel G; Miaskowski A; Gagoś M
Eur J Pharm Sci; 2017 Jan; 97():9-21. PubMed ID: 27816628
[TBL] [Abstract][Full Text] [Related]
3. Lysine enhances the effect of amphotericin B against Candida albicans in vitro.
Zhao L; Jiang J; Zhu Z; Liao Z; Yao X; Yang Y; Cao Y; Jiang Y
Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):182-93. PubMed ID: 26711896
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates.
Thanathanee O; Miller D; Ringel DM; Schaffner CP; Alfonso EC; O'Brien TP
J Ocul Pharmacol Ther; 2012 Dec; 28(6):589-92. PubMed ID: 22788845
[TBL] [Abstract][Full Text] [Related]
5. A novel formulation of solubilised amphotericin B designed for ophthalmic use.
Serrano DR; Ruiz-Saldaña HK; Molero G; Ballesteros MP; Torrado JJ
Int J Pharm; 2012 Nov; 437(1-2):80-2. PubMed ID: 22890190
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Gangadhar KN; Adhikari K; Srichana T
Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
[TBL] [Abstract][Full Text] [Related]
7. Enhancement effect of N-methyl-N″-dodecylguanidine on the vacuole-targeting fungicidal activity of amphotericin B against the pathogenic fungus Candida albicans.
Yutani M; Ogita A; Usuki Y; Fujita K; Tanaka T
J Antibiot (Tokyo); 2011 Jul; 64(7):469-74. PubMed ID: 21522157
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral
Zhou L; Zhang P; Chen Z; Cai S; Jing T; Fan H; Mo F; Zhang J; Lin R
Int J Nanomedicine; 2017; 12():4269-4283. PubMed ID: 28652732
[TBL] [Abstract][Full Text] [Related]
9. Polysorbate Surfactants as Drug Carriers: Tween 20-Amphotericin B Conjugates as Anti-Fungal and Anti-Leishmanial Agents.
Ravichandran V; Kesavan V; Cojean S; Loiseau PM; Jayakrishnan A
Curr Drug Deliv; 2018; 15(7):1028-1037. PubMed ID: 29732967
[TBL] [Abstract][Full Text] [Related]
10. The synergistic fungicidal effect of low-frequency and low-intensity ultrasound with amphotericin B-loaded nanoparticles on C. albicans in vitro.
Yang M; Xie S; Adhikari VP; Dong Y; Du Y; Li D
Int J Pharm; 2018 May; 542(1-2):232-241. PubMed ID: 29559330
[TBL] [Abstract][Full Text] [Related]
11. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
Charvalos E; Tzatzarakis MN; Van Bambeke F; Tulkens PM; Tsatsakis AM; Tzanakakis GN; Mingeot-Leclercq MP
J Antimicrob Chemother; 2006 Feb; 57(2):236-44. PubMed ID: 16361329
[TBL] [Abstract][Full Text] [Related]
12. Development of polyion complex micelles for encapsulating and delivering amphotericin B.
Wang CH; Wang WT; Hsiue GH
Biomaterials; 2009 Jul; 30(19):3352-8. PubMed ID: 19299011
[TBL] [Abstract][Full Text] [Related]
13. High purity amphotericin B.
Cleary JD; Chapman SW; Swiatlo E; Kramer R
J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats.
Radwan MA; AlQuadeib BT; Šiller L; Wright MC; Horrocks B
Drug Deliv; 2017 Nov; 24(1):40-50. PubMed ID: 28155565
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ
J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607
[TBL] [Abstract][Full Text] [Related]
16. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells.
Legrand P; Chéron M; Leroy L; Bolard J
J Drug Target; 1997; 4(5):311-9. PubMed ID: 9169988
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells.
Staedtke V; Brähler M; Müller A; Georgieva R; Bauer S; Sternberg N; Voigt A; Lemke A; Keck C; Möschwitzer J; Bäumler H
Small; 2010 Jan; 6(1):96-103. PubMed ID: 19882684
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the fungicidal activity of amphotericin B by allicin, an allyl-sulfur compound from garlic, against the yeast Saccharomyces cerevisiae as a model system.
Ogita A; Fujita K; Taniguchi M; Tanaka T
Planta Med; 2006 Oct; 72(13):1247-50. PubMed ID: 16902870
[TBL] [Abstract][Full Text] [Related]
19. Effect of amphotericin B on the metabolic profiles of Candida albicans.
Cao Y; Zhu Z; Chen X; Yao X; Zhao L; Wang H; Yan L; Wu H; Chai Y; Jiang Y
J Proteome Res; 2013 Jun; 12(6):2921-32. PubMed ID: 23672250
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
